Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis.

IF 1.8 Q3 GASTROENTEROLOGY & HEPATOLOGY Crohn's & Colitis 360 Pub Date : 2024-02-28 eCollection Date: 2024-01-01 DOI:10.1093/crocol/otae014
Michelle M Bao, Juliana M Kennedy, Michael T Dolinger, David Dunkin, Joanne Lai, Marla C Dubinsky
{"title":"Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis.","authors":"Michelle M Bao, Juliana M Kennedy, Michael T Dolinger, David Dunkin, Joanne Lai, Marla C Dubinsky","doi":"10.1093/crocol/otae014","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus (CMV) can be reactivated in ulcerative colitis (UC), but its role in progression of inflammation is unclear. Risk factors include severe colitis and treatment with immunosuppressive medications, particularly corticosteroids and immunomodulators.</p><p><strong>Methods: </strong>We report a case of cytomegalovirus colitis in a pediatric patient with pancolitis who had been refractory to aminosalicylate, infliximab, and ustekinumab and was in clinical remission and with transmural response on upadacitinib.</p><p><strong>Results: </strong>This is a case of a 13-year-old male with UC refractory to multiple therapies who were in clinical remission on upadacitinib 30 mg daily. He developed an acute increase in symptoms and did not respond to therapy escalation with increased upadacitinib 45 mg daily for 2 weeks and prednisone for 1 week. He was diagnosed with cytomegalovirus colitis on flexible sigmoidoscopy biopsy. He was treated with intravenous ganciclovir with tapering of immunosuppressive regimen. Despite initial response, he underwent subtotal colectomy and subsequent restorative proctocolectomy with ileal pouch anal-anastomosis.</p><p><strong>Conclusions: </strong>Despite our patient having multiple risk factors for developing CMV colitis, upadacitinib may have played a role when considering its known impact on the herpes family of viruses. CMV colitis should be evaluated for in any patient who presents with worsening symptoms without evidence of other infection or response to increase in therapy.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"6 1","pages":"otae014"},"PeriodicalIF":1.8000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10914341/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Crohn's & Colitis 360","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/crocol/otae014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cytomegalovirus (CMV) can be reactivated in ulcerative colitis (UC), but its role in progression of inflammation is unclear. Risk factors include severe colitis and treatment with immunosuppressive medications, particularly corticosteroids and immunomodulators.

Methods: We report a case of cytomegalovirus colitis in a pediatric patient with pancolitis who had been refractory to aminosalicylate, infliximab, and ustekinumab and was in clinical remission and with transmural response on upadacitinib.

Results: This is a case of a 13-year-old male with UC refractory to multiple therapies who were in clinical remission on upadacitinib 30 mg daily. He developed an acute increase in symptoms and did not respond to therapy escalation with increased upadacitinib 45 mg daily for 2 weeks and prednisone for 1 week. He was diagnosed with cytomegalovirus colitis on flexible sigmoidoscopy biopsy. He was treated with intravenous ganciclovir with tapering of immunosuppressive regimen. Despite initial response, he underwent subtotal colectomy and subsequent restorative proctocolectomy with ileal pouch anal-anastomosis.

Conclusions: Despite our patient having multiple risk factors for developing CMV colitis, upadacitinib may have played a role when considering its known impact on the herpes family of viruses. CMV colitis should be evaluated for in any patient who presents with worsening symptoms without evidence of other infection or response to increase in therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
严重难治性溃疡性结肠炎患者的巨细胞病毒性结肠炎。
背景:巨细胞病毒(CMV巨细胞病毒(CMV)可在溃疡性结肠炎(UC)中重新激活,但其在炎症进展中的作用尚不清楚。风险因素包括严重结肠炎和使用免疫抑制剂治疗,尤其是皮质类固醇激素和免疫调节剂:我们报告了一例儿童胰腺炎患者巨细胞病毒性结肠炎的病例,该患者曾对氨水杨酸盐、英夫利昔单抗和乌司替库单抗治疗难治,在服用达达替尼后病情得到临床缓解并出现跨膜反应:这是一例对多种疗法均难治的13岁男性UC患者,每天服用30毫克达帕替尼后临床缓解。他的症状出现急性加重,并且对每天增加达帕替尼 45 毫克治疗 2 周和泼尼松治疗 1 周的升级疗法没有反应。经柔性乙状结肠镜活检,他被诊断为巨细胞病毒结肠炎。他接受了静脉注射更昔洛韦治疗,并逐渐减少免疫抑制方案。尽管最初有所反应,但他还是接受了结肠次全切除术,随后又接受了修复性直肠结肠切除术和回肠袋肛门吻合术:结论:尽管我们的患者有多种患 CMV 结肠炎的风险因素,但考虑到达达替尼对疱疹病毒家族的已知影响,它可能起到了一定的作用。如果患者出现症状恶化,但无其他感染迹象或对增加治疗无反应,则应评估CMV结肠炎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Crohn's & Colitis 360
Crohn's & Colitis 360 Medicine-Gastroenterology
CiteScore
2.50
自引率
0.00%
发文量
41
审稿时长
12 weeks
期刊最新文献
Real-World Ustekinumab Experience in Ileum-Dominant Versus Colonic Crohn's Disease. Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease. Real-World Experience of the Association of HLADQA1*05 Allele With Loss of Response to Anti-TNF Inhibitors. Real-World Treatment Outcomes Associated With Early Versus Delayed Vedolizumab Initiation in Patients With Ulcerative Colitis. Like a Punch in the Gut: A Novel Perspective On Annual Recurrences of Ulcerative Colitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1